Lymphoma

In this video, Jakub Svoboda, MD, discusses the results of a large real-world study on brexu-cel for mantle cell lymphoma, which were presented at ASCO Annual Meeting.

In this video, Jakub Svoboda, MD, discusses an update on pirtobrutinib, which was recently approved for relapsing mantle cell lymphoma that has been previously treated with Bruton tyrosine kinase inhibitors.

In this video, Joshua Brody, MD, discusses the results of the IELSG37 randomized trial, which examined whether radiotherapy is necessary after front-line chemoimmunotherapy for patients with primary mediastinal B-cell lymphoma.

Continued administration of COVID-19 booster vaccine among patients with lymphoma appeared associated with lower COVID-19 breakthrough infection rates, according to data published in The Lancet.

Overall incidence of pediatric cancer in the United States increased 0.5% annually on average between 2003 and 2019, according to a CDC study published in Journal of the National Cancer Institute.

Treatment with anthracyclines for breast cancer or lymphoma correlated with more than two times higher risk for congestive heart failure than that of healthy controls, according to a study conducted at Mayo Clinic.

More than 80% of a cohort of adults with relapsed or refractory follicular lymphoma exhibited an overall response to subcutaneously administered epcoritamab-bysp, according to topline data from the agent’s manufacturer.

In this video, Joshua Brody, MD, discusses an update on pirtobrutinib for pretreated mantle cell lymphoma.

An international research collaboration has contributed new insights into how the gut microbiome contributes to the effectiveness of immunotherapy for cancer.

Patients diagnosed with relapsed or refractory lymphoma during pregnancy demonstrated a high rate of OS but low PFS rate, according to study results published in Blood Advances.